Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$46.75 USD
+0.47 (1.02%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $46.78 +0.03 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.75 USD
+0.47 (1.02%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $46.78 +0.03 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth C Momentum F VGM
Zacks News
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
by Zacks Equity Research
Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
Why Is United Therapeutics (UTHR) Up 8.9% Since Last Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow
by Zacks Equity Research
Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More
by Zacks Equity Research
Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.
Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024
by Zacks Equity Research
Corcept (CORT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise on robust 2024 revenue guidance.
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More
by Zacks Equity Research
Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.
Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva
by Zacks Equity Research
The United States district court for the district of New Jersey rules against Corcept (CORT) in a patent infringement lawsuit against Teva Pharmaceuticals. Stock declines.
Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Corcept (CORT) Up 0.7% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View
by Zacks Equity Research
Corcept's (CORT) third-quarter 2023 earnings and revenues surpass estimates. The company raises the full-year revenue guidance for 2023.
Why Earnings Season Could Be Great for Corcept Therapeutics (CORT)
by Zacks Equity Research
Corcept Therapeutics (CORT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Corcept Therapeutics (CORT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Corcept (CORT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer
by Zacks Equity Research
If approved, Merck's (MRK) Keytruda will be approved for a second indication in advanced gastric or GEJ cancer.
Revolution Medicines, Inc. (RVMD) Soars 23.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics
by Zacks Equity Research
Pfizer, Allogene Therapeutics and Corcept Therapeutics are included in this Analyst Blog.
Beat the Market the Zacks Way: Novo Nordisk, MakeMyTrip, Fastenal in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
FDA Approves Pfizer's (PFE) Braftovi + Mektovi for Lung Cancer
by Zacks Equity Research
Pfizer's (PFE) Braftovi + Mektovi drug combo gets label expansion for BRAF V600E-mutant non-small cell lung cancer.
Eli Lilly's (LLY) Mirikizumab Meets Crohn's Disease Study Goals
by Zacks Equity Research
Based on this data, Eli Lilly (LLY) will initiate regulatory submissions worldwide next year seeking regulatory approval for mirikizumab in Crohn's disease.
AbbVie's (ABBV) Rinvoq Meets Key Goal in Phase II Vitiligo Study
by Zacks Equity Research
AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult patients with non-segmental vitiligo.
Amgen's (AMGN) Stock Rallies Almost 5% on Broker Upgrade
by Zacks Equity Research
A Leerink Partner analyst expects accelerating pipeline news flow for Amgen (AMGN).
Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study
by Zacks Equity Research
Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegmental vitiligo.
PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data
by Zacks Equity Research
Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer.